Results 31 to 40 of about 27,235 (300)
Bispecific antibodies have been generated in many different formats and it is becoming clear that rational design alone cannot create optimal functionalities.
Stefan Dengl+12 more
doaj +1 more source
Chemical generation of bispecific antibodies [PDF]
Bispecific antibodies (BsAbs) are regarded as promising therapeutic agents due to their ability to simultaneously bind two different antigens. Several bispecific modalities have been developed, but their utility is limited due to problems with stability and manufacturing complexity.
Jie Huang+21 more
openaire +3 more sources
BackgroundImmune checkpoint inhibitors have revolutionized cancer therapy, but many patients fail to respond or develop resistance, often due to reduced T cell activity.
Oana Hangiu+27 more
doaj +1 more source
BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
Nearly four decades after their conceptualization, antibody-based therapies are slowly being added to the treatment landscape of acute myeloid leukemia (AML). While the antibody–drug conjugate gemtuzumab ozogamicin is the only antibody-based therapy that
Cecily Allen+2 more
doaj +1 more source
Phenotypic plasticity in a newly established set of EGFR inhibitor‐adapted NSCLC cell lines during adaptation and in established cell lines. Here, we introduce novel sublines of the EGFR‐mutant non‐small cell lung cancer (NSCLC) cell lines HCC827 and HCC4006 adapted to the EGFR kinase inhibitors gefitinib (HCC827rGEFI2μm, HCC4006rGEFI1μm), erlotinib ...
Tharsagini V. Nanthaprakash+6 more
wiley +1 more source
Microphysiological Systems for Comorbidity Studies: Chronic Kidney Disease and Osteoarthritis
This review highlights the potential of organ‐on‐a‐chip systems for studying comorbidities, using chronic kidney disease (CKD) and osteoarthritis (OA) as examples. It summarizes recent advances in kidney‐on‐a‐chip and joint‐on‐a‐chip models and discusses their current and potential application in investigating CKD, OA, and CKD‐OA comorbidity, aiming to
Mingying Han+7 more
wiley +1 more source
Self‐Assembling Multi‐Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma
A novel modular T‐cell engager platform, MATCH, is developed for personalized multiple myeloma therapy. MATCH uses complementary oligonucleotide‐linked Fab’ fragments to enable flexible targeting of MM antigens and controlled T‐cell activation. The system shows potent, antigen‐specific cytotoxicity in vitro and in vivo, highlighting its potential for ...
Shannuo Li+8 more
wiley +1 more source
Design Principles for Bispecific IgGs, Opportunities and Pitfalls of Artificial Disulfide Bonds
Bispecific antibodies (bsAbs) are antibodies with two binding sites directed at different antigens, enabling therapeutic strategies not achievable with conventional monoclonal antibodies (mAbs).
Lilach Vaks+9 more
doaj +1 more source
Label‐Free FET Based Biosensor for Detection of Engineered CAR T‐Cells at Single Cell Resolution
A silicon nanowire field‐effect transistor (SiNW FET) biosensor that allows for label‐free, real‐time detection and quantification of engineered Chimeric Antigen Receptor (CAR) T‐cells at single‐cell resolution is presented. By mimicking the CAR‐specific antigen interface, the platform provides highly selective analysis of individual cell surface ...
Trang Anh Nguyen‐Le+5 more
wiley +1 more source
Genetic Engineering Methods in Primary T Cells
Primary T cells can be engineered to confer them with novel therapeutic functions, allowing them to treat a variety of conditions. Genetic engineering can be either stable or transient, aiming to either express or inhibit a target gene. This review discusses the various genetic engineering tools available as well as their characteristics and ...
Anthony Youssef, Hui‐Shan Li
wiley +1 more source